Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Top 100 Creative Companies

- PMLiVE

World Health Organization prequalifies simplified oral cholera vaccine Euvichol-S

The acute diarrhoeal illness was reported to affect around 473,000 people in 2022

- PMLiVE

Cerevel Therapeutics shares positive phase 3 results for tavapadon in Parkinson’s disease

The progressive neurodegenerative disease affects seven million people worldwide

- PMLiVE

Uncovering the millennial mindset – why two thirds of HCPs feel misunderstood by pharma

By Phil Streit

- PMLiVE

Roche’s ALK inhibitor Alecensa receives FDA approval to treat early-stage NSCLC

Approximately half of all patients with early lung cancer experience cancer recurrence following surgery

- PMLiVE

Ipsen announces launch of new UK headquarters in London life sciences community

The Paddington site will serve as one of the company’s three global hubs

- PMLiVE

GSK’s shingles vaccine shown to maintain high protection in long-term study

The infectious condition affects up to one in three people globally in their lifetimes

- PMLiVE

UK scientists discover two genes offering potential drug targets against skin cancer

The three major types of skin cancer are basal cell carcinoma, squamous cell carcinoma and melanoma

- PMLiVE

Behavioural science – the route to healthcare salvation?

Industry is urged to ditch the simple slogans and instead embrace the complexity, as delving more deeply could improve success rates

- PMLiVE

The PM Society – giving back

Highlighting some of the initiatives, donations and work streams that the organisation has led

- PMLiVE

Effective Communication in Virtual Meetings: Stay Pithy – Impetus InSite Tips #4

Learn the value of concise communication in our fourth tip for optimizing virtual meetings. Discover how keeping interactions short and focused can drastically improve engagement and retention in today's fast-paced...

Impetus Digital

- PMLiVE

Takeda gains rights to Kumquat’s immune-oncology programme in deal worth over $1.2bn

The selected candidate can be developed as a monotherapy, combination therapy or both

- PMLiVE

Roche reveals promising phase 3 results for subcutaneous Ocrevus in progressive and relapsing MS

The chronic neurological condition affects more than 2.8 million people worldwide

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links